Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although stu...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
Nature Publishing Group
2017
|